» Articles » PMID: 38752106

Understanding Antithrombotic Agents for Rehabilitation Therapy: A Comprehensive Narrative Review

Overview
Journal Cureus
Date 2024 May 16
PMID 38752106
Authors
Affiliations
Soon will be listed here.
Abstract

In rehabilitation medicine, attention must be paid to the medication. Among them, antithrombotic drugs are used for the initial treatment and secondary prevention of stroke, so as a basic knowledge, the pharmacological actions, characteristics, indications, and precautions for the use of antithrombotic drugs should be known. Antithrombotic agents are divided into antiplatelet agents and anticoagulants, and the appropriate antithrombotic agent is selected according to the main disease or condition. Antiplatelet agents include aspirin, clopidogrel, ticlopidine, prasugrel, ticagrelor, and cilostazol. Each antiplatelet agent has a different mechanism of action, characteristics, and indications, and should be prescribed with due consideration. Anticoagulants include heparin, synthetic Xa inhibitors, direct oral anticoagulants (DOACs), synthetic antithrombin agents, and warfarin. Knowledge of the mechanism of action, characteristics, and indications of each anticoagulant is necessary, as well as monitoring and dose adjustment. With regard to ischemic cerebrovascular disease (ICD) and antithrombotic agents, the first step is to classify cerebral infarction and to determine whether antiplatelet agents or anticoagulants should be used. Bleeding and recurrence prevention are important considerations in the selection of appropriate antithrombotic agents for the pathophysiology of ICD.

References
1.
Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C . Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013; 369(1):11-9. DOI: 10.1056/NEJMoa1215340. View

2.
Yamashita T, Suzuki S, Inoue H, Akao M, Atarashi H, Ikeda T . Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry. Eur Heart J Qual Care Clin Outcomes. 2021; 8(2):202-213. PMC: 8888123. DOI: 10.1093/ehjqcco/qcab025. View

3.
Matsumoto S, Shimodozono M, Miyata R, Kawahira K . Effect of cilostazol administration on cerebral hemodynamics and rehabilitation outcomes in poststroke patients. Int J Neurosci. 2011; 121(5):271-8. DOI: 10.3109/00207454.2010.551431. View

4.
Iacobucci G . Covid-19: Aspirin does not improve survival for patients admitted to hospital, trial reports. BMJ. 2021; 373:n1475. DOI: 10.1136/bmj.n1475. View

5.
Natsuaki M, Morimoto T, Shiomi H, Yamaji K, Watanabe H, Shizuta S . Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019; 12(11):e008307. DOI: 10.1161/CIRCINTERVENTIONS.119.008307. View